Intercept Pharmaceuticals Inc.

NASDAQ: ICPTHealthcare / Biotechnology / USA
66.21+2.21+3.45%Vol 305 1191Y Perf -35.82%
Aug 19th, 2019 16:00
BID63.05 ASK66.99
Open65.08 Previous Close64.00
Pre-Market- After-Trading66.21
 - -%  - -%
Target Price
144.61 
Analyst Rating
Moderate Buy 1.59
Potencial %
118.41 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-100/-88/-97 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-100/-96/-99 
Growth Ranking
★+ —    -
Insiders Shares Cnt. % 3/6/12M
-100/-94/-99 
Income Ranking
 —    -
Market Cap (mil)2 165 
Earnings Rating
Sell
Price Range Ratio 52wk %
10.59 
Earnings Date
7th Aug 2019

Today's Price Range

64.4066.90

52wk Range

58.21133.74

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-4.76%
1 Month
-8.24%
3 Months
-25.94%
6 Months
-42.25%
1 Year
-35.82%
3 Years
-60.89%
5 Years
-77.52%
10 Years
-

Name / TickerPriceChg.Chg.%
ICPT66.212.21003.45
AAPL210.353.85001.86
GOOG1 198.4520.85001.77
MSFT138.412.28001.67
XOM69.451.15001.68
WFC45.250.86001.94
JNJ132.250.89000.68
FB186.172.47001.34
GE8.67-0.1200-1.37
JPM108.690.97000.90
Earnings HistoryEstimateReportedSurprise %
Q02 2019-2.51-2.289.16
Q01 2019-2.57-3.03-17.90
Q04 2018-2.42-2.97-22.73
Q03 2018-2.65-2.1817.74
Q02 2018-2.83-2.588.83
Q01 2018-3.41-3.225.57
Q04 2017-3.57-4.43-24.09
Q03 2017-3.55-2.8918.59
Earnings Per EndEstimateRevision %Trend
9/2019 QR-2.34-3.54Negative
12/2019 QR-2.38-1.71Negative
12/2019 FY-10.00-1.01Negative
12/2020 FY-9.52-10.70Negative
Next Report Date-
Estimated EPS Next Report-2.51
Estimates Count11
EPS Growth Next 5 Years %-
Volume Overview
Volume305 119
Shares Outstanding (in ths.)32 696
Trades Count3 255
Dollar Volume30 673 924
Avg. Volume834 846
Avg. Weekly Volume391 615
Avg. Monthly Volume566 949
Avg. Quarterly Volume604 823
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
12 (70.59 %)
12 (70.59 %)
12 (70.59 %)
Moderate Buy
2 (11.76 %)
2 (11.76 %)
2 (11.76 %)
Hold
2 (11.76 %)
2 (11.76 %)
1 (5.88 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
1 (5.88 %)
Strong Sell
1 (5.88 %)
1 (5.88 %)
1 (5.88 %)
RatingModerate Buy
1.59
Moderate Buy
1.59
Moderate Buy
1.65

Intercept Pharmaceuticals Inc.

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of China, where it has licensed out the product to Sumitomo Dainippon Pharma.

CEO: Mark Pruzanski

Teplephone: +1 646 747-1000

Address: 10 Hudson Yards, New York 10011, NY, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

50%50%

Bearish Bullish

32%68%

Bearish Bullish

70%30%

News